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Many of the studies of acute renal injury have been
conducted in young mice usually during their rapid growth
phase; yet, the impact of age or growth stage on the degree
of injury is unknown. To address this issue, we studied
three forms of injury (endotoxemic-, glycerol-, and
maleate-induced) in mice ranging in age from adolescence
(3 weeks) to maturity (16 weeks). The severity of injury within
each model significantly correlated with weight and age.
We also noticed a progressive age-dependent reduction
in renal cholesterol content, a potential injury modifier.
As the animals grew and aged they also exhibited stepwise
decrements in the mRNAs of HMG CoA reductase and the low
density lipoprotein receptor, two key cholesterol homeostatic
genes. This was paralleled by decreased amounts of RNA
polymerase II and the transcription factor SREBP1/2 at the
reductase and lipoprotein receptor gene loci as measured by
chromatin immunoprecipitation. Our study shows that the
early phase of mouse growth can profoundly alter renal
susceptibility to diverse forms of experimental acute renal
injury.
Kidney International (2008) 74, 674–678; doi:10.1038/ki.2008.251;
published online 18 June 2008
KEYWORDS: acute renal failure; endotoxin; maleate; rhabdomyolysis
Mice have become the most widely used animal species for
the studies of experimental acute renal failure (ARF). This is
due to their relatively low cost, the great variety of
strains±genetic modifications that are available, and the
wide range of molecular probes (for example, monoclonal
antibodies) that permit the study of specific injury pathways.
Relatively young mice (2–4 months of age) are most
commonly used, presumably because short periods of
vivarium housing mitigate time constraints and expense.
During the first 4 months of age, mice undergo rapid
growth and development. For example, widely used CD-1
mice approximately triple their body weight from 3 to 16
weeks of age. It has previously been demonstrated that as
rodents advance from adulthood into old age (for example,
from B6 months to B2 years), increasing susceptibility to
ischemic ARF results.1–6 This may arise from a progressive
loss of renal functional reserve, and possible aging-induced
renal biochemical changes. In contrast, the potential impact
of the early growth period (for example, the first 1–4 months
of life) on renal susceptibility to injury has not been well
defined. Hence, this study was conducted as an initial
exploration of this issue.
RESULTS AND DISCUSSION
Between 3 and 16 weeks of age, the employed CD-1 mice
manifested rapid growth, with an approximate tripling of
body weight (Figure 1, left panel). This is consistent with data
from the animal supplier (Charles River Laboratories,
Wilmington, MA, USA). A proportionate increase in kidney
mass was observed, as denoted by a near constant relation-
ship between single kidney vs total body weight (B0.65%;
Figure 1, right panel). To test whether susceptibility to ARF is
altered during this time frame, the mice were categorized as
being ‘juvenile’ (age 3–4 weeks), ‘adolescent’ (5–6 weeks), or
‘mature’ (10–16 weeks) and challenged with intravenous
endotoxin (lipopolysaccharide; Zager et al.7), intramuscular
glycerol,8–10 or intraperitoneal maleate11–13 injection. These
three ARF models were chosen for study because they induce
renal injury by highly divergent mechanisms. Endotoxemia
causes a predominantly hemodynamic form of ARF,7,14,15 as
evidenced by renal vasoconstriction, but maintenance of
essentially normal renal histology (for example, Zager et al.7).
As shown in Figure 2 (left panel), the severity of
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lipopolysaccharide-induced ARF directly correlated with
animal age/weight, as assessed either by relative degrees of
azotemia for the three age groups (Po0.001) or by the
overall correlation coefficients between individual mouse
weights vs blood urea nitrogen (BUN) concentrations. In
contrast to lipopolysaccharide, glycerol evokes a structural
form of ARF, as denoted by proximal tubule necrosis and
heme protein cast formation.8–10 This results from glycerol-
induced rhabdomyolysis and hemolysis, with subsequent
heme iron-driven proximal tubule oxidative stress.8–10 Again,
a striking correlation between age/body weight and the
severity of ARF was observed, whether injury severity was
assessed functionally (BUN, Figure 2) or by renal histology
(Figure 3). In contrast to glycerol and lipopolysaccharide,
which induce both extrarenal and renal injury, maleate
toxicity is specific for the proximal tubule.12,13,16 This is due
to the selective maleate transport/uptake by this nephron
segment.11,16 With subsequent intracellular metabolism,13
toxic intermediaries result producing mitochondrial dysfunc-
tion and a profound ATP depletion state. This culminates in
a form of injury that recapitulates most critical features of
post-ischemic ARF.12 Using this maleate model, a striking
direct relationship between animal weight/age and the
severity of ARF was again observed, as gauged by BUN
(Figure 2) and renal histology (Figure 3). It is notable that the
greatest variation in renal injury with each of the three ARF
models was found in the ‘adolescent’ age group (for example,
BUN coefficients of variation as high as 65%). This implies
that it is during this intermediate time frame that the most
profound transition from an ‘injury-resistant’ to an ‘injury-
sensitive’ phenotype occurs. Finally, it is notable that
increasing either the maleate or glycerol dosages in ‘juvenile’
mice failed to induce the same degree of injury that was
observed in ‘mature’ mice with lesser toxin doses (Figure 4).
This underscores the relative degree of protection that the
youngest mice express. Finally, although this study used male
CD-1 mice, we have observed comparable degrees of
protection in young female mice, and this correlates with
body weight. Thus, the above-described results do not appear
to be gender specific.
The explanation for the profound impact of rapid mouse
growth/development on ARF susceptibility remains un-
known, but it undoubtedly represents a fertile avenue for
future study. It is almost certainly multifactorial in nature,
and may well operate via different pathways in different ARF
models. In an attempt to demonstrate that the rapid growth
phase can, in fact, alter the expression of specific injury-
modifying molecules, we sought age-dependent differences in
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Figure 1 | Body weight and single kidney weight (as expressed
as a percent of total body weight). There was an approximate
three-fold difference in mean body weight for the mice that
comprised the three experimental groups. However, single kidney
weight remained a relatively constant percent of total body
weight.
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Figure 2 | Severity of ARF for the three age groups, as
assessed by BUN concentrations. With each of three ARF
models, the severity of renal dysfunction increased with
advancing age. The P-values compare the youngest vs the oldest
groups, whereas the r values reflect the overall correlation
coefficients between individual body weights and BUN
concentrations for each ARF model (n¼ 6–10 mice per group).
Baseline BUN concentrations were 25±2 mg per 100 ml and did
not significantly differ between the groups.
Figure 3 | Renal histology. Examples of renal histology obtained
from mice in the ‘juvenile’ vs the ‘mature’ mouse groups that
were subjected to the maleate (a, b) or glycerol (c, d) model.
Maleate-treated ‘juvenile’ mice maintained essentially normal
histology (a). Conversely, fulminant tubular necrosis with cast
formation was observed in the ‘mature’ group subjected to
maleate injection (b). Glycerol had a minimal effect on renal
histology in ‘juvenile’ mice (c). However, glycerol induced marked
tubular necrosis and cast formation when administered to
‘mature’ mice (d).
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the expression of renal cholesterol, a previously well-
documented renal cytoprotectant.17–20 In the aftermath of
acute tubular injury, cellular cholesterol levels rise. This
stabilizes the plasma membrane, and hence, prevents plasma
membrane rupture during superimposed toxic or ischemic
stress.17–20 Therefore, we questioned whether the highest
renal cholesterol levels might be observed in the youngest
mice, with progressive age-related reductions thereafter.
Indeed, as shown in Figure 5 (left panel), this was the
case. Renal tubular cholesterol content primarily reflects
de novo HMG (3-hydroxy-3-methylglutaryl) CoA reductase
(HMGCR)-driven synthesis, and low-density lipoprotein
receptor (LDL-R)-mediated cholesterol extraction from
plasma.17–20 To assess whether, or which, of these pathways
might be operative, we measured HMGCR mRNA and LDL-R
mRNA levels during the studied growth period. As shown in
Figure 6, both HMGCR and LDL-R mRNAs progressively
decreased with advancing age, paralleling the reductions in
cholesterol content. This suggests that both synthetic and
uptake pathways may contribute to the observed age-
dependent differences in renal cholesterol content. Notably,
serum cholesterol progressively increased with age despite
decreasing renal cholesterol levels (Figure 5, right panel).
Although by no means conclusive, this reciprocal relationship
between renal and serum cholesterol levels would be
consistent with increased LDL-R-mediated cholesterol extrac-
tion from blood, and thereby, rising renal cholesterol levels.
To test whether the above-noted changes in HMGCR
mRNA and LDL-R mRNA levels reflected differences in gene
transcription, rather than simply a potential difference in
mRNA stabilities, we measured RNA polymerase II (Pol II)
densities at the start and end exons of the HMGCR and LDL-
R genes by microplate-based matrix chromatin immunopre-
cipitation (ChIP) technology (see Materials and Methods).
Notably, Pol II density is both a mediator of and a surrogate
marker for rates of gene transcription.21–23 Indeed, at both
start and end HMGCR and LDL-R gene exons, Pol II
expression decreased with advancing age, thereby paralleling
the observed mRNA and cholesterol declines (Figure 7). To
further assess whether age-dependent differences in renal
cholesterol content are reflected by differences in gene
regulation, densities of Pol II, SREBP-1, and SREBP-2 (sterol
regulatory element-binding protein transcription factors 1, 2;
Thewke et al.24 and Edwards et al.25) at two sites within the
HMGCR promoter were assessed. Again consistent with the
mRNA data, the youngest mice had the highest amounts of
Pol II, SREBP-1, and SREBP-2 at the HMGCR promoter
(Figure 8). The fact that Pol II and SREBP densities at silent
genes (rDNA, b globin) did not vary according to age
(Figure 9) indicates the specificity of the above-noted Pol II/
SREBP results. Thus, the entire assessed HMGCR cholesterol
synthetic axis (from m transcription factors at the promoter
- m Pol II at the promoter- m Pol II along the gene- m
mRNA - m cholesterol) was relatively overexpressed in
the ‘juvenile’ vs the ‘mature’ animals. Of even broader
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Figure 5 | Renal cortical and serum cholesterol levels in
various mouse age groups. As the mice matured from the
youngest to the oldest group, a progressive reduction in renal
cortical cholesterol content was observed. Conversely, serum
cholesterol levels manifested the opposite trend, as stepwise
increases were seen with growth (n¼ 7–8 per group).
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Figure 6 | mRNA levels of HMG CoA reductase (HMGCR) and
low-density lipoprotein receptor (LDL-R) in renal cortex in
‘juvenile,’ ‘adolescent,’ and ‘mature’ mice. Both HMGCR and
LDL-R mRNAs manifested a stepwise decline with age (n¼ 5–6 per
group).
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Figure 4 | Effects of increasing maleate and glycerol dosages
in ‘juvenile’ mice on the severity of ARF. (left panel) Increasing
maleate from 600 to 800 mg/kg failed to induce azotemia in
‘juvenile’ mice. At 1000 mg/kg, toxicity was apparent, but it
was significantly less than that observed in ‘mature’ mice at a
600 mg/kg maleate dosage. (right panel) Increasing glycerol
dosage from 9 to 12 mg/kg in ‘juvenile’ mice induced azotemia,
but it was significantly less than that observed in ‘mature’
mice (n¼ 5–10 per group).
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significance than these specific findings, the Pol II and SREBP
data underscore the great potential utility of matrix ChIP
assay for studying in vivo genomic and, potentially,
epigenomic events in in vivo renal tissue.
Finally, we emphasize that we do not conclude that the
cholesterol pathway is responsible for the age-dependent
differences in ARF susceptibility noted in this study. Rather,
the age-dependent changes within the cholesterol axis simply
illustrate the dynamic nature of cellular processes that are in
flux during early growth and development. Undoubtedly,
changing levels of many other injury modifiers, such as
growth factors (for example, epidermal growth factor, insulin
like growth factor and hepatic growth factor), cell-cycle
regulatory proteins (for example, p21), and potent cytopro-
tective molecules (for example, heme oxygenase-1) could also
be in flux during 1–4 months of age. In light of these
theoretical considerations, and the results of the present
study, it would appear that great attention needs to be paid to
mouse age when conducting studies of this type. Finally, the
present study indicates that matrix ChIP assay is a powerful
new tool that can be applied to the study of such issues.
MATERIALS AND METHODS
ARF protocols
All experiments were conducted using male CD-1 mice (Charles
River Laboratories) that were obtained at either 2–3 weeks (weight
B17 g) or 4–5 weeks (weight B25 g) of age. They were maintained
under routine vivarium conditions with free food and water access.
They were arbitrarily assigned to one of the three age groups:
‘juvenile’, 3–4 weeks, B20 g; ‘adolescent’, 5–6 weeks, B30 g; or
‘mature’, 10–16 weeks,B40 g). The ‘mature’ group consisted of mice
that were obtained either at 2–3 weeks or at 4–5 weeks of age and
allowed to mature in this institution’s vivarium. Because the age and
weight of the mice represented a continuum within and between
groups (rather than fixed arbitrary values), the results from the ARF
experiments were compared between both the arbitrary groups and
as overall correlations between age/weight vs the severity of ARF
(as gauged by BUN concentrations). The following three ARF
models were used: (1) an Escherichia coli endotoxemic model of
ARF (2 mg/kg via tail vein injection; Zager et al.7); Na maleate
nephrotoxicity (600 mg/kg, i.p.; Zager et al.12); and (3) glycerol-
induced ARF (50% solution; 9 ml/kg, administered in a divided
intramuscular dose in each hindlimb; Zager10). Approximately
18–20 h after injections, the mice were anesthetized with pentobar-
bital (40–50 mg/kg, i.p.), a serum sample was obtained from the vena
cava for BUN analysis, and the kidneys were resected and prepared
for ChIP and mRNA analyses. Kidneys from the ‘juvenile’ and
‘mature’ mouse groups that underwent the maleate or glycerol
challenges were cut longitudinally, fixed in 10% buffered formalin,
4 mm sections were cut and stained (hematoxylin and eosin, H&E),
and examined by light microscopy to evaluate the extent of injury
(tubular necrosis, cast formation).
Baseline renal assessments
The following baseline parameters for the mice in different age
groups were assessed: (1) single kidney weight (given as percentage
(%) of total body weight); (2) BUN concentrations; (3) renal
cortical mRNAs for HMGCR and LDL-R (reverse transcription-
PCR; Zager et al.20, Zager and Kalhorn26, and Zager et al.27,28);
SREBP-2(at −100 bp)SREBP-1(at −100 bp)Pol II(at −400 bp)Pol II(at −100 bp)
HMGCR promoter region
0
0.5
1
1.5
2
2.5
3
D
en
si
ty
 (%
 in
pu
t)
P<0.001 P<0.001 P<0.001 P<0.001
Juvenile,,
Mature,,
Figure 8 | Pol II, SREBP-1, and SREBP-2 at the HMGCR
promoter region in ‘juvenile’ and ‘mature’ mice. Pol II was
measured at two sites within the promoter (100 and 400 base
pairs, bp, from 50-end to transcription start site, TSS), whereas the
SREBPs were measured only at the 100 bp region. The amount
of Pol II and both SREBPs were B2–3 higher in the younger
mouse kidneys (n¼ 6 for each).
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Figure 9 | ‘Negative’ controls for Pol II and SREBP recruitment.
(left panel) Pol II levels were assessed at ribosomal DNA (rDNA)
and there was no difference between the ‘juvenile’ and ‘mature’
groups. (right panel) The amounts of both SREBPs at a ‘silent’
(b globin) gene were equal for both mouse groups (n¼ 6
determinations for each).
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Figure 7 | RNA polymerase II (Pol II) density at target gene
loci, as assessed by matrix ChIP assay (Flanagin et al.30). Pol II
was assessed at the start (exon 1) and end exons of the HMGCR
and LDL-R genes. The ‘juvenile’ mice had higher Pol II densities at
both HMGCR exons (no. 1 and no. 19) and both LDL-R exons
(no. 1 and no. 18) than in the ‘mature’ mice. These results exactly
paralleled the directional changes seen in their cognate
mRNAs (n¼ 6 determinations per group).
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(4) renal cortical cholesterol content (gas chromatography; Zager
and Kalhorn26); (5) RNA Pol II density at the start and end exons of
the HMGCR and LDL-R gene (tissues prepared as per Naito et al.29,
and assayed by microplate-based matrix ChIP assay30); (6) Pol II
density at the HMGCR promoter (100 and 400 bp; 50-end to
transcription start site); (7) SREBP-1 and SREBP-2 (transcription
factors) at the HMGCR promoter (100 bp); and (8) ‘negative
controls’: Pol II at 18S ribosomal DNA (rDNA; Flanagin et al.30);
SREBP-1 and SREBP-2 at a ‘silent’ kidney gene (b globin). ChIP
DNA data were expressed as a fraction of input DNA.30 All values
were given as means±1 s.e.m. Statistical analyses were performed
either by unpaired Student’s t-testing for analyzing two sets of data,
by analysis of variance if multiple groups were compared (after
testing by Student’s t-test with Bonferroni correction), and by
calculating correlation coefficients.
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